Autoimmune Hepatitis

What Is Autoimmune Hepatitis?

AIH occurs when the immune system mistakenly targets liver tissue, producing ongoing inflammation that may silently progress for months or years [3][4].

• AIH is a diagnosis of pattern recognition: typical labs, autoantibodies, elevated IgG, compatible histology, and exclusion of other causes [1][2].
• “Interface hepatitis” on biopsy (often with plasma cells) is a classic finding, but must be interpreted with the clinical picture [2][8].
• AIH can occur at any age and in all sexes; it is more common in women and often coexists with other autoimmune diseases [1][3].

Types and Overlap Syndromes

AIH is commonly described as type 1 (often ANA/SMA-positive) and type 2 (often anti-LKM1-positive), but real-world care focuses on phenotype, severity, and treatment response rather than labels [2][6].

• Overlap syndromes (AIH-PBC or AIH-PSC) may be suspected when cholestatic labs, bile duct injury, or imaging findings suggest concurrent cholangiopathy [2][5].
• Triggers are not always identifiable; genetics and immune dysregulation are thought to contribute [3][5].

Symptoms and How It Presents

AIH ranges from asymptomatic lab abnormalities to chronic fatigue and jaundice, and in some cases can present as acute severe hepatitis or acute liver failure [1][3].

• Common symptoms: fatigue, nausea, poor appetite, right upper abdominal discomfort, joint pains, jaundice [7].
• Many patients have no symptoms initially; diagnosis may follow routine blood tests [3].
• Signs of advanced disease: ascites, variceal bleeding, encephalopathy—these warrant urgent specialty evaluation [4].

Diagnosis: What Your Team Looks For

Diagnosis is based on clinical context plus laboratory and (often) biopsy evidence, while excluding viral, drug-induced, metabolic, and biliary causes [1][4].

Treatment: Induction, Maintenance, and Alternatives

Standard therapy aims to suppress immune-mediated injury and achieve biochemical remission (normalization of aminotransferases and IgG) [1][2].

• Induction: corticosteroid-based therapy (often prednisone/prednisolone), frequently combined with azathioprine [2][1].
• Maintenance: lowest effective immunosuppression to keep labs normal and prevent relapse [2].
• Alternatives (selected cases): budesonide (in non-cirrhotic patients) or second-line agents when intolerance/nonresponse occurs [2][5].

Treatment decisions are individualized. Active cirrhosis, acute severe presentations, pregnancy plans, infection risk, diabetes, osteoporosis, and medication interactions all matter [1][2].

Monitoring and “Remission”

AIH is typically a long-term condition. Monitoring focuses on confirming remission, detecting relapse early, and minimizing treatment toxicity [1][2].

• Regular labs (ALT/AST, bilirubin, INR, albumin) and IgG trends [2].
• Bone health, glucose, blood pressure, and infection surveillance when on steroids/immunosuppression [2].
• Relapse is common if therapy is stopped too early; tapering/withdrawal decisions should be specialist-led [2][5].

Liver Transplant Considerations

Liver transplantation is considered for end-stage cirrhosis, liver failure, or (less commonly) acute liver failure from AIH when medical therapy cannot stabilize the disease [1][10].

• Recurrence can occur after transplant. Autoimmune liver diseases (including AIH) can recur in a subset of patients and may require adjustments to immunosuppression and close follow-up [11][12][13].
• Overlap syndromes: AIH-PBC or AIH-PSC can influence post-transplant monitoring strategies [11][13].
• Medication literacy matters: post-transplant immunosuppression is essential; do not stop or change meds without your transplant team [11].